Prespecified subgroup analyses showed that primary surgery conferred greater benefits for patients with stage III disease and ...

New research suggests that an antibody-drug conjugate may offer practice-changing, patient-friendly treatment of blastic ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

The world’s largest meeting on cancer research has brought promising updates on treatment and prevention for colorectal ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable ...

Five early-career Fred Hutch/UW researchers received prestigious Young Investigator Awards from Conquer Cancer, the ASCO Foundation during this year's annual meeting of the American Society of ...

At the 2025 ASCO (American Society of Clinical Oncology) Annual Meeting, Dr. Armenian presented findings from the session ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

New data support the role of structured exercise and low inflammatory diets to improve survival and quality of life following ...

Investigators created a prognostic digital pathology-based AI score to identify a subset of patients with clinically high-risk prostate cancer more likely to benefit from the addition of abiraterone ...